Medidata Solutions, Inc. (NASDAQ:MDSO) - Equities researchers at SunTrust Banks reduced their Q3 2017 EPS estimates for shares of Medidata Solutions in a research report issued on Wednesday. SunTrust Banks analyst S. Draper now expects that the company will post earnings of $0.19 per share for the quarter, down from their previous forecast of $0.21. SunTrust Banks currently has a “Buy” rating and a $90.00 target price on the stock.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.03. The company had revenue of $137.41 million during the quarter, compared to analyst estimates of $134.28 million. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. Medidata Solutions’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same period last year, the business earned $0.24 EPS. WARNING: “Q3 2017 EPS Estimates for Medidata Solutions, Inc. Lowered by Analyst (NASDAQ:MDSO)” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://stocknewstimes.com/2017/07/21/q3-2017-eps-estimates-for-medidata-solutions-inc-lowered-by-analyst-nasdaqmdso.html.
A number of other analysts have also weighed in on MDSO. J P Morgan Chase & Co upped their price objective on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a research note on Tuesday. Citigroup Inc. reaffirmed a “buy” rating and issued a $94.00 price objective (up from $77.00) on shares of Medidata Solutions in a research note on Monday, July 10th. Piper Jaffray Companies upped their price objective on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a research note on Friday, July 7th. Zacks Investment Research raised shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research note on Wednesday, May 3rd. Finally, Morgan Stanley set a $74.00 price objective on shares of Medidata Solutions and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $76.83.
Medidata Solutions (NASDAQ MDSO) opened at 75.78 on Friday. The company has a 50 day moving average of $77.53 and a 200 day moving average of $63.59. The company has a market capitalization of $4.27 billion, a price-to-earnings ratio of 128.66 and a beta of 1.81. Medidata Solutions has a 52 week low of $46.10 and a 52 week high of $85.92.
In other news, COO Michael L. Capone sold 5,000 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $69.46, for a total transaction of $347,300.00. Following the transaction, the chief operating officer now owns 171,754 shares in the company, valued at $11,930,032.84. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael I. Otner sold 7,500 shares of the company’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $66.39, for a total transaction of $497,925.00. Following the transaction, the executive vice president now owns 78,419 shares in the company, valued at approximately $5,206,237.41. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,139 shares of company stock worth $1,259,466. Corporate insiders own 5.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Acrospire Investment Management LLC acquired a new position in shares of Medidata Solutions during the first quarter valued at $121,000. LS Investment Advisors LLC increased its position in shares of Medidata Solutions by 44.6% in the first quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock valued at $191,000 after buying an additional 1,021 shares during the period. World Asset Management Inc acquired a new position in shares of Medidata Solutions during the first quarter valued at $201,000. Miles Capital Inc. acquired a new position in shares of Medidata Solutions during the first quarter valued at $202,000. Finally, Oppenheimer & Close LLC acquired a new position in shares of Medidata Solutions during the first quarter valued at $210,000.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
